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SUMMARY
Pediatric allogeneic hematopoietic cell transplantation (HCT) practices dif-
fer from those of adults, particularly the heterogeneity of transplantable
nonmalignant diseases and the lower incidence of graft-versus-host disease
(GVHD). Several guidelines regarding the management of acute (a) GVHD
in adult HCT have been published. We aimed to capture the real-life
approaches for pediatric aGVHD prophylaxis/treatment, and data from 75/
193 (response rate 39%) EBMT centers (26 countries) were included, repre-
senting half (48%) of the pediatric EBMT-HCT activity. Results with ≥75%
approval from respondents (74/75) for GVHD prophylaxis after myeloabla-
tive HCT for malignancies partially contradict published guidelines: Single-
agent cyclosporine A (CsA) was used for matched sibling donor HCT in
47%; blood CsA levels were reported lower; the relapse risk in malignant
diseases influenced GVHD prophylaxis with early withdrawal of CsA; dis-
tinct longer duration of CsA was employed in nonmalignant diseases. Most
centers used additional anti-thymocyte globulin for matched unrelated and
mismatched donor HCT, but not for matched siblings. Regarding prophy-
laxis in nonmyeloablative conditioning (mainly for nonmalignant diseases),
responses showed broad heterogeneity. High conformity was found for first-
line treatment; however, results regarding steroid-refractory aGVHD indi-
cate an earlier diagnosis in children. Our findings highlight the need for
standardized pediatric approaches toward aGVHD prophylaxis/treatment
differentiated for malignant and nonmalignant underlying diseases.
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Introduction
Pediatric allogeneic hematopoietic stem cell transplanta-
tion (HCT) is an established treatment for a range of
malignant and nonmalignant diseases. Graft-versus-host
disease (GVHD) remains one of the main barriers to
the success of HCT. Acute GVHD (aGVHD) and subse-
quent chronic GVHD, including associated long-term
sequelae, may be more devastating in children who are
still growing and developing [1-4].
Both preventive and treatment strategies for pediatric
aGVHD vary, and the optimal practice is not well defined.
Protocols, which may superficially appear similar, often har-
bor significant dissimilarities, challenging the interpretation
of published outcome data, particularly if combined adult
and pediatric data sets with different age-groups and under-
lying diagnoses are evaluated. GVHD prophylaxis varies
according to drug, dosage, route of administration, and
duration. Steroids are almost universally used as first-line
treatment for aGVHD, but the details and definitions of
steroid refractoriness (SR) vary considerably. Since pediatric
HCT is performed for a wide range of underlying diseases,
and pediatric aGVHD differs from adult aGVHD in terms
of incidence, severity, and response to treatment, the Pedi-
atric Diseases Working Party (PDWP) of the European
Society of Blood and Marrow Transplantation (EBMT) sur-
veyed centers performing pediatric HCT and collated infor-
mation on prophylactic and treatment strategies in aGVHD.
The present study aimed to harmonize this data with a view
to standardizing strategies and compare our results with the
published mainly adult recommendations [5-7]. We wanted
to investigate the variations in the definition of SR-aGVHD
in use in daily clinical practice, which is important to the
GVHD community [8]. Furthermore, we aimed to identify
areas of heterogeneity and disagreement to improve design
and feasibility of future interventional pediatric studies.
Materials and methods
In November 2018, we updated a survey that was ini-
tially performed in 2014 in which 193 EBMT centers
performing pediatric HCT were invited to participate.
The first questionnaire included 80 questions relating to
practices in aGVHD prophylaxis in myeloablative or
reduced-intensity conditionings for malignant and non-
malignant diseases, segregated regarding stem cell
source, donor specifics, HLA-matching, and graft
manipulation; furthermore, respondents were asked for
practice patterns regarding first, second and subsequent
treatment line both for acute and chronic GVHD,
including details about the use of monoclonal and poly-
clonal antibodies. Based on the answers of the first
questionnaire, and after discussion within the board of
the PDWP of the EBMT, we then designed a focused
second questionnaire (25 questions), which was sent to
the same centers that had completed the first question-
naire. This second survey focused on aGVHD prophy-
laxis regarding (i) myeloablative for mainly malignant
underlying diseases or reduced-intensity conditionings
for mainly nonmalignant diseases, (ii) donor details
[matched sibling donors (MSD), matched unrelated
donors (MUD), and mismatched donors (MMD),
including haplo-identical donors], and (iii) stem cell
source (peripheral blood stem cells, bone marrow;
excluding cord blood) and aGVHD first- and second-
line treatment only, including definitions of steroid-re-
fractory aGVHD. Details of haplo-identical HCT and
post-transplant cyclophosphamide were not included, as
we aimed for the most common settings. The response
rate for some individual questions varied and is indi-
cated by the denominator in the text. The results of the
second questionnaire were discussed in an expert work-
shop of the PDWP of the EBMT in November 2018 in
Frankfurt.
Data were analyzed at the EBMT PDWP Data Office
in Paris, France. For statistical analyses IBM SPSS
Statistics for Windows, version 19 (IBM Corp.,
Armonk, NY, USA) were used. Pearson coefficient cor-
relation was utilized to determine correlations between
at least two continuous variables. Data were analyzed
using R version 2.13.0 and exported to Excel 2013 ver-
sion 15.0 (Microsoft Excel).
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Results
A total of 75/193 (39%) centers participated, represent-
ing almost half (48%) of the allogeneic pediatric HCT
activity within the EBMT. Ninety-two percent (69/75)
of the responding centers transplanted pediatric patients
only and six centers transplanted both adults and chil-
dren. The distribution of center size seemed quite bal-
anced with 46% (34/75) of centers performing more
than the mean number of pediatric HSCTs per year
2014 according to the EBMT registry. We were able to
include data about practice patterns from 67% (26/39)
of countries registered within the EBMT in 2014 for
performing pediatric HCT. The numbers of responding
centers from each participating country are shown in
Fig. 1.
GVHD prophylaxis in HCT with myeloablative
conditioning for mainly malignant underlying diseases
MSD
Of 74 respondents to this question, cyclosporine A
(CsA) alone was routinely used by 47% (35/74), and a
combination of CsA and a short course of methotrex-
ate (MTX) was used by 45% (33/74) of the responding
centers when bone marrow (BM) was the stem cell
source. Of note, the use of peripheral blood as the
stem cell source (PBSC) did not change the choice of
prophylaxis in 73% (54/74) of the centers, although
details were not provided. Additional anti-thymocyte
globulin (ATG) was given in 21% (16/74) of the cen-
ters.
MUD
A combination of CsA and MTX was used by 95% (45/
47) of the 47 responding centers when BM was the stem
cell source. Again, in the majority of responding centers
(85%, 40/47) the use of PBSC did not change GVHD
prophylaxis. ATG was added to this regimen by 81%
(38/47) of the centers.
MMD
A combination of CsA and MTX was used by 88% (65/
74) of the 74 responding centers, and ATG was added
in 96% (71/74). Ex vivo T-cell depletion (TCD) was
employed by 67% (50/74) of the centers. The use of
PBSC in MMD did not influence the choice of prophy-
laxis in 93% (69/74) of the centers.
ATG
ATG for GVHD prophylaxis in myeloablative condition-
ing (MAC) HCT for malignancies was used in MUD and
MMD HCT in 81% (60/74) and 96% (71/74) of the 74
responding centers, respectively (Table 1). ATG was used
in MSD HCT in 21% (16/74) of the centers. More specifi-
cally, centers were asked to provide details of ATG
administration. Of 71 respondents, 48% (34/71) used
thymoglobulin (Genzyme, Cambridge, MA, USA), 27%
(19/71) used grafalon (Neovii Biotech, Lexington, MA,
USA), and 25% (18/71) used both agents. The median
daily dose of thymoglobulin was 2.5 mg/kg, which was
usually given on three consecutive days (starting day
between day 7 and day 3). The median daily dose of
grafalon was 10 mg/kg, which was also usually given on
three consecutive days (starting day between day 6 to
and day 3). Among the ATG schedules in MSD, MUD,
or MMD HCT, no meaningful differences were reported.
Ex vivo TCD
T-cell depletion was used by 67% (50/74) of the 74
responding centers, usually for MMD HCT. Within these
centers, positive selection with anti-CD34 antibodies was
used in 78% (39/50) and negative selection in 44% (22/
50). CD3/19 depletion was predominantly used (93%, 20/
22), and only 7% (2/22) used “Alemtuzumab in the bag”
(i.e., adding Alemtuzumab to the stem cell infusate [29]).
Pharmacologic immunosuppression in addition to TCD
was administered in 47% (35/74), mostly with CsA (86%,
30/35).
CsA administration
The details of CsA administration revealed a homogenous
practice, and those with agreement in more than two-thirds
of the 75 responding centers are summarized (Table 1).
The particularities of CsA prophylaxis with lower
concordance included initial doses of 2 mg/kg/day
(11%, 8/75), 1 mg/kg/day (10%, 7/75), and 4–6 mg/kg/
day (15%, 11/75). The dose and scheduling of short-
course MTX administration and leucovorin rescue var-
ied as follows: 10 mg/m2 MTX on days +1, +3, and +6
in 37% (28/75); 15 mg/m2 MTX on day +1, and
10 mg/m2 MTX on days +3, +6, +11 in 27% (20/75).
Furthermore, 25% (19/75) of the centers used the latter
schedule with omitting MTX on day +11.
Targeted CsA blood concentrations at weeks 1, 2–4,
and 8 were requested and 69 of 75 centers responded.
We found that 88% (61/69) of the responding centers
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reported no difference in the target level within the first
8 weeks. Importantly, the majority of the centers (85%,
59/69) aimed for a post-transplant target level <200 ng/
ml with an equal distribution between 100–150 and 160–
200 ng/ml. A trend toward a lower target concentration
in MSD recipients could be surveyed (data not shown).
Of note, 77% (60/75) of the centers reported that the
estimated relapse risk of the underlying malignant dis-
ease influenced CsA prophylaxis. This observation was
supported by a clear difference in the duration of CsA
prophylaxis when the relapse risk was categorized as
“high and low” (Fig. 2a, 74/75 responding centers). A
comparison between malignant and nonmalignant dis-
eases revealed a longer duration of CsA prophylaxis in
patients with nonmalignant diseases (Fig. 2b 74/75
responding centers). GVHD prophylaxis containing
immunosuppressive agents other than CsA varied con-
siderably (Table 1B, 74/75 responding centers).
GVHD prophylaxis in HCT with reduced-intensity
conditioning in mainly nonmalignant underlying
diseases
While prophylactic regimens, mainly applied in nonma-
lignant HCT showed broad variety, the combination of
CsA + MTX was most frequently used by the 69
respondents to this question (Fig. 3, 69/75 responding
centers). More specifically, centers were asked about the
details of the CsA regime: The majority of the centers
reported no differences regarding donor and stem cell
sources; regarding the targeted CsA blood levels, 68%
(47/69) of the responding centers reported a CsA target
level <200 ng/ml, similar to that of MAC. Of note, in
our survey a concentration of >200 ng/ml was reported
more often in RIC than in MAC regimens (16%, 11/69
vs 24%, 17/69 in MAC) and a concentration of
≤200 ng/ml was reported more often in MAC regimens
(24%, 17/69 vs 11%, 8/69 in RIC, data not shown).
Additional ATG was employed by 90% (62/69) of the
centers, with the majority (73%, 45/62) of these using
the same regimen as for MAC conditioning, although
the median dose for grafalon was higher in RIC than
MAC (20 mg/kg/day vs. 10 mg/kg/day).
The time to taper or withdraw immunosuppressive
treatment was influenced by the chimeric status of
patients in 90% (62/69) of the centers.
Treatment for aGVHD
First-line treatment
All centers (75/75) indicated corticosteroids as first-line
treatment for aGVHD ≥grade 2 that was started using
mainly intra-intravenously methylprednisolone at the
dose of 2 mg/kg/day in two doses. Specifics of first-line
treatment, which were reported by the majority of the
75 responding centers, are summarized in Fig. 4. More
detailed, the overall severity of aGVHD influenced the
initial dosing in only 35% (26/75) of the centers. A dose
of 1–2 mg/kg/day was used for grade 1 or 2 involve-
ment of the skin only. The duration of the initial treat-
ment was 1 week in 40% (30/75), 5 days in 25% (19/
75), and >10 days in 25% (19/75) of the centers (mean,
8 days; range, 2–15 days). Dose reduction was based on
response (57%, 43/75) or preplanned schedule (43%,
32/75). Different tailing schedules were described, but a
25% dose reduction every 3–7 days was most common.
A total of 74% (55/74) of the 74 responding centers
reported the use of topical agents for aGVHD: For gas-
trointestinal GVHD the use of topical steroids, and for
cutaneous GVHD the use of topical steroids and topical
tacrolimus were reported without further details.
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Figure 1 Participating countries
(N = 26) of 39 (67%) countries
registered within the European
Society of Blood and Marrow
Transplantation in 2014 for
performing pediatric hematopoietic
cell transplantation and number of
participating centers. Responding
centers (N = 75 of 75 participating
centers).
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Definitions of steroid resistance
Centers were questioned about the clinical criteria for
definition of steroid resistance (SR), and time point of
the assessment (duration of steroid treatment in days)
and 68/75 centers responded. Sixty-seven (45/68) per-
cent of centers stated to diagnose SR of aGVHD within
the first 5 days after treatment start. In greater detail,
centers were asked whether the clinical diagnosis of SR
was based on the progression of aGVHD in any organ,
failure to improve in the individual organ, or failure to
improve in the overall severity grading of aGVHD
(Fig. 5). Failure to show improvement in the individual
aGVHD organ was the main criterion and was used by
87% (59/68) of the responding centers. For each of the
three clinical criteria of SR in use, we found distinct dif-
ferent time points of assessment. SR was diagnosed early
when progression of aGVHD in any organ was the SR
criterion (used by 71%, 48/68). Patients were allowed a
longer period to respond before SR was diagnosed when
Table 1. Acute graft-versus-host disease prophylaxis in hematopoietic cell transplantation with myeloablative
conditioning for mainly malignant underlying diseases. (A) Cyclosporine A (CsA); details with agreement in more than
two-thirds of the 74 responding centers of 75 participating centers are summarized. (B) Other agents than CsA.
A. MSD MUD MMD
aGVHD prophylaxis with CsA (N = 74)
CsA alone 35/74 (47%)
CsA + MTX 33/74 (45%) 70/74 (95%) 65/74 (88%)
Other 6/74 (8%) 4/74 (5%) 9/74 (12%)
Additional ATG 16/74 (21%) 60/74 (81%) 71/74 (96%)
TCD 50/74 (67%)
No influence of SC-source (BM/PBSC) 54/74 (73%) 63/74 (85%) 69/74 (93%)
Regime of CsA administration (N = 75)
Start day 1 66/75 (90%)
i.v. 64/75 (85%)
2 doses 63/75 (84%)
3 mg/kg 56/75 (75%)
CsA WB level 71/75 (95%)
CsA WB level at C-0 73/75 (97%)
Duration Median 110 days (IQR 90)
WB target level below 200 ng/ml (N = 69) 59/69 (85%)
WB target level <100 ng/ml 9/59 (15%)
WB target level 100–150 ng/ml 22/59 (37%)
WB target level 160–200 ng/ml 20/59 (34%)
WB target level >200 ng/ml 8/59 (14%)
Influence of relapse risk of underlying disease (N = 74) 57/74 (77%)
Taper before discontinuation (N = 74) 72/74 (97%)
Leucovorin rescue (N = 72) 63/72 (87%)
i.v. 61/63 (97%)
24 h post-MTX 52/63 (82%)
B. aGVHD prophylaxis
with other agents
(N = 74)
N (%) of
centers Details N (%) Comments
Tacrolimus 14/74 (19%) i.v. 13/14 (90%)
WB level <10 ng/ml 8/14 (60%) Influence of relapse risk: 11/14 (80%)
WB level >10 ng/ml 6/14 (40%)
MMF 32/74 (43%) Duration: median 45 days Usually in combination with
CNI: 28/32 (89%)
Alemtuzumab 16/71 (23%) in MUD
ATG, anti-thymocyte globulin; BM, bone marrow; C-0, lowest blood concentration reached before the next dose is adminis-
tered; CNI, calcineurin inhibitor; CsA, cyclosporine A; i.v., intravenous; IQR, interquartile range; MAC, myeloablative condition-
ing; MMD, mismatched donor; MMF, mycophenolate mofetil; MSD, matched sibling donor; MTX, methotrexate; MUD,
matched unrelated donor; PBSC, peripheral blood stem cell; TCD, T-cell depletion; WB, whole blood.
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failure to improve in an individual organ was the crite-
rion. Importantly, up to 2 weeks was allowed by centers
using failure to improve the overall severity grading of
aGVHD (used by 56%, 38/68 of the responding cen-
ters).
Second-line treatment
A broad inter-center variety has been reported by 74/75
centers regarding the choice of second-line treatment
for aGVHD (Fig. 6). However, a more detailed evalua-
tion was beyond the scope of this survey. Second-line
treatments were combined with aGVHD prophylactic
drugs by 98% (73/74) of the responding centers, but in
92% (68/74) of the centers, steroids were discontinued
when new drugs were introduced. Similar to first-line
treatment, organ involvement of aGVHD did not affect
the choice of second-line treatment in 60% (44/73) of
73 responding centers.
Discussion
The present survey aimed to study the real-life
approaches of prevention and treatment of aGVHD by
indication and conditioning intensity (MAC for mainly
malignant; RIC for mainly nonmalignant diseases) of
pediatric HCT. The data have shown high agreement
for aGVHD prophylaxis in MAC HCT for mainly
malignancies which reveals that there are important dis-
similarities when compared to published mainly adult
recommendations [5–7]. We have summarized the
results that have shown said agreement in more than
two-thirds of the 74 (74/75) responding centers in
Table 1 to offer a platform for further optimization of
aGVHD prophylaxis [10]. In contrast, our results show
a broad variety regarding aGVHD prophylaxis in RIC
HCT reflecting the complexity of HCT for
nonmalignant pediatric diseases like inborn errors. We
also aimed to collect details of the definition of SR-
aGVHD currently used in clinical practice, which is of
interest to the GVHD community. The development of
biomarkers for GVHD would expand the opportunity
for clinical research in this field [12]. Since many bio-
marker studies combine adult and pediatric data, the
findings of our study may aid the interpretation of
those results. Differences between pediatric and adult
practice patterns of prophylaxis and treatment may
reflect (i) differences of immune reconstitution between
adult and pediatric patients [12] and (ii) the hetero-
geneity of underlying diseases (particularly pediatric
malignant and nonmalignant diseases). Our results
highlight the need of a clear definition of SR in aGVHD
within studies, since the reported earlier diagnosis of SR
in pediatric aGVHD when compared to adult recom-
mendations (≤5 days in 66% of responding centers)
allows the earlier introduction of second-line therapies.
This may also impact the inclusion criteria of prospec-
tive studies.
In 1997 and 2012, Ruutu et al. [5,6,9] published sur-
veys of aGVHD prophylaxis and treatment in adult
HCT patients as well as recommendations on behalf of
the EBMT and European LeukemiaNet (ELN WG). In
2000, the EBMT PDWP published a survey of aGVHD
practices in children [7]. A recent pediatric study by
Cuvelier et al. [11] underlined the importance of the
prevention of grades 2–4 aGVHD, which was again
shown to be a major risk factor for chronic GVHD.
The approach to aGVHD prophylaxis for children
differs from that in adult practice essentially in MAC
HCT for mainly malignant diseases. Children undergo-
ing MSD HCT received CsA alone as GVHD prophy-
laxis in nearly half of all centers, whereas 87% of the
adult centers used a combination of CsA + MTX. Weiss
et al. [13] reported a superior outcome for relapse rate
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Figure 2 Duration of cyclosporine A
(CsA) prophylaxis after myeloablative
conditioning (MAC). (a) Duration of
CsA prophylaxis regarding the relapse
risk of malignant underlying disease
(low relapse risk versus high relapse
risk). (b) Duration of CsA prophylaxis
regarding the underlying disease
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underlying disease). Responding
centers (N = 74 of 75 participating
centers).
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and 5-year event-free survival, with no increase in
GVHD incidence for children undergoing MSD HCT
for leukemia who had received CsA alone (versus
CsA + MTX). The addition of ATG in MUD and
MMD HCT was more frequently used in pediatric com-
pared with adult practice (81% and 96% for MUD and
MMD, respectively, compared with 57% for adults).
EBMT and ELN (EBMT ELN) recommend the use of
ATG at the clinician’s discretion, indicating the need for
further studies to define the role of ATG [14].
Similarly, ex vivo TCD was more commonly used by
pediatric centers (67% vs. 28% in adults) and typically
in MMD HCT. TCD was not included in the adult rec-
ommendations [5,6,9]. Of note, the use of PBSC as the
stem cell source in MAC HCT for malignancies did not
change the choice of prophylaxis in the majority of the
responding centers regardless of the donor type.
Our results suggest that clinical situations influence
practice. The relapse risk of an underlying malignancy
clearly shapes GVHD prophylaxis in pediatric centers,
resulting in earlier withdrawal of CsA. While the influ-
ence of the persistence of minimal residual disease was
not within the scope of this survey, it may impact
future GVHD prophylaxis. In contrast, patients with
nonmalignant diseases received prolonged CsA prophy-
laxis. The paucity of the detailed published data on
GVHD prophylaxis may limit the interpretation of out-
come data regarding GVHD incidence, disease course,
and biomarkers.
A high inter-center agreement has been reported
among pediatric centers for CsA target levels; however,
this approach differed from that of adult practice as the
majority of the pediatric centers used a lower target
level (<200 ng/ml) without a higher target level during
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Figure 3 Graft-versus-host disease
prophylaxis in transplantation with
reduced-intensity conditioning for
mainly nonmalignant diseases.
Responding centers (N = 69 of 75
participating centers).
79 85
94 96
58
15
75
55
0
10
20
30
40
50
60
70
80
90
100
%
 o
f r
es
po
ni
ng
 c
en
te
rs
 (N
 =
 7
5)
Indication Methylprednisolone Predniso(lo)ne Further aspects of first-line treatment
Corticosteroids
Figure 4 First-line treatment for
acute graft-versus-host disease.
Responding centers (N = 75 of 75
participating centers). Relapse risk of
underlying malignant disease.
768 Transplant International 2020; 33: 762–772
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Lawitschka et al.
the first weeks. This is in contrast to the recommenda-
tion by the EBMT ELN (200–300 ng/ml within the first
3–4 weeks post-transplant). A lower incidence of grade
II–IV aGVHD was reported when target CsA trough
levels are achieved early in the post-transplantation per-
iod, with the time to achieving the target CsA concen-
tration being significant [15,16]. CsA blood
concentrations show high inter- and intra-individual
variability; therefore, age-adjusted prospective studies
with innovative approaches may offer a new insight into
the optimal target and schedule [17].
The EBMT ELN recommendation of CsA prophylaxis
for 6 months in adults is in striking contrast to our
results that showed that around 70% of the centers
stopped CsA prior to or at day +100 in patients with
malignant diseases. The findings emphasize the require-
ment for different approaches to GVHD prophylaxis in
children with malignant and nonmalignant diseases,
since patients with nonmalignant diseases do not benefit
from a graft-versus-leukemia/GVHD effect and require
a more aggressive approach to GVHD prevention.
Our survey found that a less intensive approach to
CsA prophylaxis undergoing MAC HCT for malignan-
cies is likely to be related to a lower incidence and a
milder clinical course of pediatric aGVHD when com-
pared with those of adults [1,4].
While the use of MTX was similar in pediatric and
adult practices, leucovorin rescue was more commonly
used in children (85% vs. 49%). Tacrolimus was more
commonly used in pediatric compared with adult cen-
ters (19% vs. 7%). European experience with tacrolimus
seems to be more limited than that of the United States
[18–20]. Pediatric centers employed mycophenolate
mofetil (MMF) in GVHD prophylaxis in MAC HCT
more frequently than adult centers (43% vs. 12%), but
details are lacking. No adult consensus recommenda-
tions are available.
Regarding the RIC setting, fewer pediatric centers used
CsA + MMF (30% vs. 69%), and TCD was more com-
mon (15% vs. 3%). The EBMT ELN recommendations
for RIC conditioning endorse CsA + MMF plus ATG in
MUD HCT. Beside the great disparity in pediatric RIC
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prophylaxis, higher planned CsA target levels were
reported. Only pediatric patients with nonmalignant dis-
eases – mainly form the RIC cohort in which GVHD
offers no benefit – were targeted for higher CsA blood
levels >200 ng/m. Our survey confirmed the wide variety
of RIC regimens reported in a previous EBMT PDWP
survey [21]. Since the mid-90s multiple RIC regimens for
HCT in nonmalignant diseases have been developed in a
variety of pediatric HCT centers but randomized studies
comparing RIC HCT with conventional intensity condi-
tioning in children are scarce [30]. This reflects the clini-
cal practice of pediatricians who face an enormous
variety of transplant indications that require a patient-
adapted strategy, particularly for the huge variety of
immunodeficiency syndromes [21].
First-line treatment for aGVHD in children shows
good consensus with most recommendations
[2,9,22,23]. Histological confirmation of aGVHD was
required more often by pediatric compared with adult
centers (24% vs. 18%) but occurred less often than pre-
viously reported [23].
We have focused our survey on aspects which apply
for the most common pediatric HCT settings, which is
why several important evaluable parameters are missing
in this survey, particularly ATG schedules, GVHD pro-
phylaxis in cord blood HCT, and details of steroid
taper. Another limitation of our survey is the response
rate of 39% (75/193) which is about or even slightly
above average [31]. It seems probable that response
rates from those centers with more interest in GVHD
were higher, but we have limited ability to explore this
response bias.
Our results suggest that the majority of pediatric
centers consider patients to be SR for aGVHD after a
shorter period of time compared with adult practice.
Unsurprisingly, when the criterion for SR was progres-
sion in any organ, SR was diagnosed early, with the
majority of the centers (62%) diagnosing first-line
treatment failure after 3 days. The EBMT ELN recom-
mendation is diagnosis of SR after 5 days. SR was most
commonly defined as failure to improve in the individ-
ual organ. The time point for evaluation was mainly
between 5 and 7 days after starting steroid treatment.
There are no pediatric data to support the recommen-
dation that initiating second-line treatment on day five
or earlier improves outcome, and a prospective study
to evaluate this is required. Nevertheless, a more pre-
cise definition of SR should be considered to facilitate
prospective GVHD and biomarker studies [8].
Our survey showed second-line treatment to be as
variable in children as it is in adults, with two
exceptions: MMF (43% vs. 33%) and extracorporeal
photopheresis (ECP; 30% vs. 17%). Pediatric preference
for ECP may reflect the published recommendations
and data [24–26]. The pediatric preference for MMF
may reflect daily clinical experience [23], although the
published results are less encouraging [22,27].
Our survey results showing that pediatric approaches
are divergent in some aspects of aGVHD prophylaxis
and treatment has been included in recent consensus
recommendations of the EBMT about the prophylaxis
and management of graft-versus-host disease after HCT
for hematological malignancies [32]. Another impact of
our study results is that a harmonized recommendation
for the CsA blood levels has been included into the
study protocol of the ALL SCTped 2012 FORUM study.
Regarding SR of aGVHD treatment, we are aiming to
implement the two following definitions: either (i) pro-
gression of aGVHD in any organ within 3 days or (ii)
failure to show improvement in the individual aGVHD
organ within 7 days in a prospective second-line treat-
ment study for aGVHD in pediatric and adolescent
patients.
Adult practice and recommendations often form the
basis of pediatric practice; therefore, our results com-
paring pediatric real-life approaches with published
adult surveys and recommendations provide useful
information on which to judge the appropriateness of
this approach. The benefit of standardization of prophy-
laxis and treatment for aGVHD is obvious [28]; how-
ever, our findings highlight the need for different
approaches for children with malignant and various
nonmalignant underlying diseases.
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